Literature DB >> 11314047

Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas.

M Labuhn1, G Jones, E J Speel, D Maier, C Zweifel, O Gratzl, E G Van Meir, M E Hegi, A Merlo.   

Abstract

In many human cancers, the INK4A locus is frequently mutated by homozygous deletions. By alternative splicing this locus encodes two non-related tumor suppressor genes, p16(INK4A) and p14(ARF) (p19(ARF) in mice), which regulate cell cycle and cell survival in the retinoblastoma protein (pRb) and p53 pathways, respectively. In mice, the role of p16(INK4A) as the critical tumor suppressor gene at the INK4A locus was challenged when it was found that p19(ARF) only knock-out mice developed tumors, including gliomas. We have analysed the genetic status of the INK4A locus in 105 primary gliomas using both microsatellite mapping (MSM) and quantitative real-time PCR (QRT-PCR). Comparison of the results of the two methods revealed agreement in 67% of the tumors examined. In discordant cases, fluorescence in situ hybridization (FISH) analysis was always found to support QRT-PCR classification. Direct assessment of p14(ARF) exon 1beta, p16(INK4A) exon 1alpha and exon 2 by QRT-PCR revealed 43 (41%) homozygous and eight (7%) hemizygous deletions at the INK4A locus. In 49 (47%) gliomas, both alleles were retained. In addition, QRT-PCR, but not MSM, detected hyperploidy in five (5%) tumors. Deletion of p14(ARF) was always associated with co-deletion of p16(INK4A) and increased in frequency upon progression from low to high grade gliomas. Shorter survival was associated with homozygous deletions of INK4A in the subgroup of glioblastoma patients older than 50 years of age (P=0.025, Anova test single factor, alpha=0.05).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314047     DOI: 10.1038/sj.onc.1204197

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.

Authors:  Andrew J Davies; Andreas Rosenwald; George Wright; Abigail Lee; Kim W Last; Dennis D Weisenburger; Wing C Chan; Jan Delabie; Rita M Braziel; Elias Campo; Randy D Gascoyne; Elaine S Jaffe; Konrad Muller-Hermelink; German Ott; Maria Calaminici; Andrew J Norton; Lindsey K Goff; Jude Fitzgibbon; Louis M Staudt; T Andrew Lister
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

2.  Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression.

Authors:  Matthias Simon; Christian Simon; Gertraud Köster; Volkmar H J Hans; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-10       Impact factor: 4.130

3.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

Review 4.  Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.

Authors:  Hua Mao; Drake G Lebrun; Jingxuan Yang; Vivian F Zhu; Min Li
Journal:  Cancer Invest       Date:  2012-01       Impact factor: 2.176

5.  Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.

Authors:  Kenichi Kohashi; Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Tomonari Takahira; Yukiko Takahashi; Tatsuro Tajiri; Tomoaki Taguchi; Sachiyo Suita; Masazumi Tsuneyoshi
Journal:  J Cancer Res Clin Oncol       Date:  2008-04-02       Impact factor: 4.553

6.  Highly aggressive behavior of malignant rhabdoid tumor: a special reference to SMARCB1/INI1 gene alterations using molecular genetic analysis including quantitative real-time PCR.

Authors:  Kenichi Kohashi; Yoshinao Oda; Hidetaka Yamamoto; Sadafumi Tamiya; Teiyu Izumi; Shigeru Ohta; Tomoaki Taguchi; Sachiyo Suita; Masazumi Tsuneyoshi
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

Review 7.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

8.  BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression.

Authors:  Dorothea Douglas; Jessie Hao-Ru Hsu; Long Hung; Aaron Cooper; Diana Abdueva; John van Doorninck; Grace Peng; Hiro Shimada; Timothy J Triche; Elizabeth R Lawlor
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

9.  GSK3beta regulates differentiation and growth arrest in glioblastoma.

Authors:  Serdar Korur; Roland M Huber; Balasubramanian Sivasankaran; Michael Petrich; Pier Morin; Brian A Hemmings; Adrian Merlo; Maria Maddalena Lino
Journal:  PLoS One       Date:  2009-10-13       Impact factor: 3.240

10.  Glioblastoma Multiforme Oncogenomics and Signaling Pathways.

Authors:  Okezie O Kanu; Betsy Hughes; Chunhui Di; Ningjing Lin; Jinrong Fu; Darell D Bigner; Hai Yan; Cory Adamson
Journal:  Clin Med Oncol       Date:  2009-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.